Gestational trophoblastic neoplasia medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
==Chemotherapy== | ==Chemotherapy== | ||
Low-Risk Gestational Trophoblastic Neoplasia (FIGO Score 0–6) | |||
Treatment commonly used treatment regimens include the following: | |||
* The 8-day Charing Cross regimen. Methotrexate (50 mg intramuscularly [IM] on days 1, 3, 5, and 7) and folinic acid (7.5 mg orally on days 2, 4, 6, and 8). This may be the most common regimen worldwide | |||
* Biweekly pulsed dactinomycin (1.25 mg/m2 IV) | |||
* Weekly methotrexate (30 mg/m2 IM). Efficacy of this regimen appears to be low for choriocarcinoma and for patients with Féderation Internationale de Gynécologie et d’Obstétrique (FIGO) risk scores of 5 to 6 | |||
Other regimens in less-common use include the following: | |||
* An 8-day regimen of methotrexate (1 mg/kg IM days 1, 3, 5, and 7) and folinic acid (0.1 mg/kg IM days 2, 4, 6, and 8) | |||
* Methotrexate 20 mg/m2 IM days 1 to5, repeated every 14 days | |||
* Dactinomycin 12 μg/kg/day IV days 1 to 5, repeated every 2 to 3 weeks | |||
* Methotrexate 20 mg IM daily, days 1 to 5; and dactinomycin 500 μg IV daily, days 1 to 5, repeated every 14 days | |||
* Dactinomycin 10 μg/kg/day, days 1 to 5, repeated every 2 weeks | |||
* Methotrexate 0.4 mg/kg/day IM daily on days 1 to 5, repeated after 7 days | |||
* Etoposide 100 mg/m2/day IV on days 1 to 5, or 250 mg/m2 IV on days 1 and 3, at 10-day intervals | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Gynecology]] | [[Category:Gynecology]] | ||
Revision as of 21:09, 7 October 2015
Template:Choriocarcinoma Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Chemotherapy
Low-Risk Gestational Trophoblastic Neoplasia (FIGO Score 0–6) Treatment commonly used treatment regimens include the following:
- The 8-day Charing Cross regimen. Methotrexate (50 mg intramuscularly [IM] on days 1, 3, 5, and 7) and folinic acid (7.5 mg orally on days 2, 4, 6, and 8). This may be the most common regimen worldwide
- Biweekly pulsed dactinomycin (1.25 mg/m2 IV)
- Weekly methotrexate (30 mg/m2 IM). Efficacy of this regimen appears to be low for choriocarcinoma and for patients with Féderation Internationale de Gynécologie et d’Obstétrique (FIGO) risk scores of 5 to 6
Other regimens in less-common use include the following:
- An 8-day regimen of methotrexate (1 mg/kg IM days 1, 3, 5, and 7) and folinic acid (0.1 mg/kg IM days 2, 4, 6, and 8)
- Methotrexate 20 mg/m2 IM days 1 to5, repeated every 14 days
- Dactinomycin 12 μg/kg/day IV days 1 to 5, repeated every 2 to 3 weeks
- Methotrexate 20 mg IM daily, days 1 to 5; and dactinomycin 500 μg IV daily, days 1 to 5, repeated every 14 days
- Dactinomycin 10 μg/kg/day, days 1 to 5, repeated every 2 weeks
- Methotrexate 0.4 mg/kg/day IM daily on days 1 to 5, repeated after 7 days
- Etoposide 100 mg/m2/day IV on days 1 to 5, or 250 mg/m2 IV on days 1 and 3, at 10-day intervals